Your search for bevacizumab returned 11 results

The Agency could not approve the BLA due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence.

Lonsurf is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor.

Increased recurrence-free survival seen for patients with high-risk HCC following resection or ablation.

At the end of one year, likelihood of being weaned off treatment was higher for eyes treated with aflibercept versus bevacizumab

Outcomes at 2 years comparable among patients with diabetic macular edema receiving aflibercept monotherapy, bevacizumab first

The sBLA was based on efficacy and safety data from the KEYNOTE-A18 trial.

Researchers say they have identified an unintended effect of Medicare’s 340B Drug Pricing Program; increases in spending for outpatient cancer treatments among patients with commercial insurance.

Researchers looked at the use of 6 biosimilars across 38 oncology practices and found that biosimilar use increased from 2019 to 2021.

The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.

Substantial improvement observed through month 12, which persisted through month 60, but lessened with fewer treatments